Cell Reports
(May 2020)
Interplay between Liver X Receptor and Hypoxia Inducible Factor 1α Potentiates Interleukin-1β Production in Human Macrophages
Louise Ménégaut,
Charles Thomas,
Antoine Jalil,
Jean Baptiste Julla,
Charlène Magnani,
Adam Ceroi,
Louise Basmaciyan,
Adélie Dumont,
Wilfried Le Goff,
Mano Joseph Mathew,
Cédric Rébé,
Valentin Dérangère,
Aline Laubriet,
Valentin Crespy,
Jean-Paul Pais de Barros,
Eric Steinmetz,
Nicolas Venteclef,
Philippe Saas,
Laurent Lagrost,
David Masson
Affiliations
Louise Ménégaut
Université Bourgogne Franche-Comté, LNC UMR1231, 21000 Dijon, France; INSERM, LNC UMR1231, 21000 Dijon, France; FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000 Dijon, France; CHRU Dijon Bourgogne, Laboratory of Clinical Chemistry, 21000 Dijon, France
Charles Thomas
Université Bourgogne Franche-Comté, LNC UMR1231, 21000 Dijon, France; INSERM, LNC UMR1231, 21000 Dijon, France; FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000 Dijon, France
Antoine Jalil
Université Bourgogne Franche-Comté, LNC UMR1231, 21000 Dijon, France; INSERM, LNC UMR1231, 21000 Dijon, France; FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000 Dijon, France
Jean Baptiste Julla
Centre de Recherche des Cordeliers, INSERM, Université de Paris, IMMEDIAB Laboratory, 75006 Paris, France
Charlène Magnani
Université Bourgogne Franche-Comté, LNC UMR1231, 21000 Dijon, France; INSERM, LNC UMR1231, 21000 Dijon, France; FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000 Dijon, France
Adam Ceroi
Université Bourgogne Franche-Comté, EFS Bourgogne Franche-Comté, INSERM, UMR1098, 25000 Besançon, France; FCS Bourgogne-Franche Comté, LipSTIC LabEx, 25000 Besançon, France
Louise Basmaciyan
UMR A PAM, Équipe Vin, Aliment, Microbiologie, Stress, Université Bourgogne Franche-Comté, AgroSup Dijon, 21078 Dijon Cedex, France; Parasitology-Mycology Department, University Hospital of Dijon, 21000 Dijon, France
Adélie Dumont
Université Bourgogne Franche-Comté, LNC UMR1231, 21000 Dijon, France; INSERM, LNC UMR1231, 21000 Dijon, France; FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000 Dijon, France
Wilfried Le Goff
Sorbonne Université, Inserm, Institute of Cardiometabolism and Nutrition (ICAN), UMR_S1166, Hôpital de la Pitié, Paris 75013, France
Mano Joseph Mathew
Centre de Recherche des Cordeliers, INSERM, Université de Paris, IMMEDIAB Laboratory, 75006 Paris, France
Cédric Rébé
Université Bourgogne Franche-Comté, LNC UMR1231, 21000 Dijon, France; INSERM, LNC UMR1231, 21000 Dijon, France; FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000 Dijon, France; Centre Georges-François Leclerc, Cancer Biology Research Platform, 21000 Dijon, France
Valentin Dérangère
Université Bourgogne Franche-Comté, LNC UMR1231, 21000 Dijon, France; INSERM, LNC UMR1231, 21000 Dijon, France; FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000 Dijon, France; Centre Georges-François Leclerc, Cancer Biology Research Platform, 21000 Dijon, France
Aline Laubriet
CHRU Dijon Bourgogne, Department of Cardiovascular Surgery, 21000 Dijon, France
Valentin Crespy
CHRU Dijon Bourgogne, Department of Cardiovascular Surgery, 21000 Dijon, France
Jean-Paul Pais de Barros
Université Bourgogne Franche-Comté, LNC UMR1231, 21000 Dijon, France; INSERM, LNC UMR1231, 21000 Dijon, France; FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000 Dijon, France; Lipidomic Analytic Platform, UBFC, 21000 Dijon, France
Eric Steinmetz
CHRU Dijon Bourgogne, Department of Cardiovascular Surgery, 21000 Dijon, France
Nicolas Venteclef
Centre de Recherche des Cordeliers, INSERM, Université de Paris, IMMEDIAB Laboratory, 75006 Paris, France
Philippe Saas
Université Bourgogne Franche-Comté, EFS Bourgogne Franche-Comté, INSERM, UMR1098, 25000 Besançon, France; FCS Bourgogne-Franche Comté, LipSTIC LabEx, 25000 Besançon, France
Laurent Lagrost
Université Bourgogne Franche-Comté, LNC UMR1231, 21000 Dijon, France; INSERM, LNC UMR1231, 21000 Dijon, France; FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000 Dijon, France
David Masson
Université Bourgogne Franche-Comté, LNC UMR1231, 21000 Dijon, France; INSERM, LNC UMR1231, 21000 Dijon, France; FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000 Dijon, France; CHRU Dijon Bourgogne, Laboratory of Clinical Chemistry, 21000 Dijon, France; Corresponding author
Journal volume & issue
Vol. 31,
no. 7
Abstract
Read online
Summary: Low-grade inflammation is constitutive of atherosclerosis, and anti-inflammatory therapy inhibiting interleukin-1β (IL-1β) reduces the rate of cardiovascular events. While cholesterol accumulation in atheroma plaque and macrophages is a major driver of the inflammatory process, the role of the LXR cholesterol sensors remains to be clarified. Murine and human macrophages were treated with LXR agonists for 48 h before Toll-like receptor (TLR) stimulation. Unexpectedly, we observe that, among other cytokines, LXR agonists selectively increase IL1B mRNA levels independently of TLR activation. This effect, restricted to human macrophages, is mediated by activation of HIF-1α through LXR. Accordingly, LXR agonists also potentiate other HIF-1α-dependent pathways, such as glycolysis. Treatment of human macrophages with carotid plaque homogenates also leads to induction of IL1B in an LXR-dependent manner. Thus, our work discloses a mechanism by which cholesterol and oxysterols trigger inflammation in atherosclerosis. This suggests perspectives to target IL-1β production in atherosclerotic patients.
Keywords
WeChat QR code
Close